The key asset of SNJ is a novel thrombolytic enzyme dissolving occlusive blood clots, or thrombi. While the formation of a blood clot at the site of injury is essential for wound healing, any intravascular blood clot or thrombus, resulting in occlusion could cause fatal vascular diseases such as ischemic stroke, acute myocardial infarction, pulmonary embolism, venous thromboembolism, etc. Unfortunately, current thrombolytic drug contributes to fatal bleeding and tissue damage, discouraging its use for thrombolytic patients after treatment window, 4.5 hours since the onset of the symptoms.
Our team identified a novel enzyme, thrombase SH1, which can dissolve intravascular thrombi without any bleeding complications (Circulation Research, 2021). Unlike current thrombolytics with systemic hemorrhagic risk, thrombase SH1 specifically lyses occlusive blood clots, thereby dissolving intravascular thrombi without causing any systemic bleeding. This could potentially extend the treatment window time, broadening the patient population that qualifies for acute treatment. Our patented thrombase SH1 provides the first safe therapeutic agent to treat fatal thrombotic diseases such as ischemic stroke and heart attack. It is in the preclinical stage with a top-scored NIH grant. We anticipate finishing the preclinical studies for IND approval and entering the clinical stage within 3 years. Upon development, this would potentially benefit 200 million patients who could not receive current thrombolytic treatment due to treatment window and bleeding risk.
Specific to Pathologic Thrombotic Clots
No Interference of Wound Healing
No Concerns of Fatal Bleeding Risk
Thrombolytic agents for intravascular clots.